Wikipedia -WSS

Wikipedia

author：fashion 2025-10-01 23:02:18 - browse：415

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Covid misinformation case heads to Supreme Court

hotspot

WSS

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

New lawsuit accuses health insurer Cigna of denying claims in bulk

ARCH Venture Partners is raising $3 billion for a life sciences fund

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Medicare drug price negotiation’s day in court

Woodcock on FDA’s accelerated approval and her next chapter

knowledge

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

SAMSHA loosens regulations on methadone treatment centers

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

United colonoscopy coverage change 'may cost lives,' doctors say

New Alzheimer's drugs heat up race for early detection blood tests

Activists slam private health insurers over coverage restrictions

Juul spent big to court Black leaders to promote its e

Supreme Court strikes down use of affirmative action

Former reverend arrested for allegedly killing 8

explore

Rise in cancer among younger people worries and puzzles doctors

Even great ERs can’t make up for American health disparities

Vertigo drug brings hope for rare neuron disorder, Niemann

ARCH Venture Partners is raising $3 billion for a life sciences fund

In the gardens at Boston Children's Hospital, families find sanctuary

Device maker Teleflex to acquire urology company for $600M

Wikipedia

hotspot

focus

leisure time